Pretax income is the income that a company earns before paying income taxes. Dogwood Therapeutics's pretax income for the
three
months ended in Sep. 2024 was $-2.28 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-5.73 Mil.
Dogwood Therapeutics's pretax margin was %.
Dogwood Therapeutics Pre-Tax Income Historical Data
The historical data trend for Dogwood Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dogwood Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Dogwood Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dogwood Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dogwood Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Dogwood Therapeutics's Pre-Tax Income falls into.
Dogwood Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Dogwood Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dogwood Therapeutics (NAS:DWTX) Pre-Tax Income Explanation
Dogwood Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dogwood Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Dogwood Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DWTX has been successfully added to your 